Nurexone Biologic Stock Performance
| NRX Stock | 0.55 0.01 1.79% |
The company secures a Beta (Market Risk) of -0.31, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning NurExone Biologic are expected to decrease at a much lower rate. During the bear market, NurExone Biologic is likely to outperform the market. At this point, NurExone Biologic has a negative expected return of -0.23%. Please make sure to verify NurExone Biologic's treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if NurExone Biologic performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days NurExone Biologic has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in March 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
1 | Zacks SCR reiterates 400 percent upside call on Nurexone Biologic for risk-tolerant investors - Kursiv Media | 12/04/2024 |
2 | Nurexone Biologic Inc. Appoints Dr. Tali Kizhner as its New Director of RD -January 21, 2025 at 0420 pm EST - Marketscreener.com | 01/21/2025 |
| Begin Period Cash Flow | 2.5 M | |
| Free Cash Flow | -3.1 M |
NurExone |
NurExone Biologic Relative Risk vs. Return Landscape
If you would invest 68.00 in NurExone Biologic on November 3, 2024 and sell it today you would lose (13.00) from holding NurExone Biologic or give up 19.12% of portfolio value over 90 days. NurExone Biologic is currently producing negative expected returns and takes up 4.8692% volatility of returns over 90 trading days. Put another way, 43% of traded stocks are less volatile than NurExone, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
NurExone Biologic Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NurExone Biologic's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NurExone Biologic, and traders can use it to determine the average amount a NurExone Biologic's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0468
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NRX |
Estimated Market Risk
| 4.87 actual daily | 43 57% of assets are more volatile |
Expected Return
| -0.23 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average NurExone Biologic is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NurExone Biologic by adding NurExone Biologic to a well-diversified portfolio.
NurExone Biologic Fundamentals Growth
NurExone Stock prices reflect investors' perceptions of the future prospects and financial health of NurExone Biologic, and NurExone Biologic fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NurExone Stock performance.
| Return On Equity | -2.54 | ||||
| Return On Asset | -1.14 | ||||
| Current Valuation | 35.4 M | ||||
| Shares Outstanding | 70.89 M | ||||
| Price To Book | 9.25 X | ||||
| EBITDA | (4.09 M) | ||||
| Net Income | (3.64 M) | ||||
| Total Debt | 1.98 M | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (2.94 M) | ||||
| Earnings Per Share | (0.10) X | ||||
| Total Asset | 2.17 M | ||||
| Retained Earnings | (14.06 M) | ||||
About NurExone Biologic Performance
Evaluating NurExone Biologic's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if NurExone Biologic has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NurExone Biologic has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
NurExone Biologic is entity of Canada. It is traded as Stock on V exchange.Things to note about NurExone Biologic performance evaluation
Checking the ongoing alerts about NurExone Biologic for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NurExone Biologic help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NurExone Biologic generated a negative expected return over the last 90 days | |
| NurExone Biologic has some characteristics of a very speculative penny stock | |
| NurExone Biologic has high historical volatility and very poor performance | |
| NurExone Biologic has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (3.64 M) with loss before overhead, payroll, taxes, and interest of (1.44 M). | |
| NurExone Biologic generates negative cash flow from operations | |
| Latest headline from news.google.com: Nurexone Biologic Inc. Appoints Dr. Tali Kizhner as its New Director of RD -January 21, 2025 at 0420 pm EST - Marketscreener.com |
- Analyzing NurExone Biologic's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NurExone Biologic's stock is overvalued or undervalued compared to its peers.
- Examining NurExone Biologic's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NurExone Biologic's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NurExone Biologic's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NurExone Biologic's stock. These opinions can provide insight into NurExone Biologic's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for NurExone Stock Analysis
When running NurExone Biologic's price analysis, check to measure NurExone Biologic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NurExone Biologic is operating at the current time. Most of NurExone Biologic's value examination focuses on studying past and present price action to predict the probability of NurExone Biologic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NurExone Biologic's price. Additionally, you may evaluate how the addition of NurExone Biologic to your portfolios can decrease your overall portfolio volatility.